While the findings in the p21 KO mouse model demonstrate a role for p21 in lung fibrosis, the complete absence of p21 prior to disease onset in this model complicates interpretation of results and prevents the assessment of targeting p21 for therapeutic applications in fibrotic disease. This evidence concerns the gene CDKN1A and pulmonary fibrosis.